Lung Cancer Interception Research Team - Stand Up To Cancer

Research Teams

Research  >  Research Portfolio  >  Research Teams  >  Lung Cancer Interception Research Team

SU2C–LUNGevity–American Lung Association Lung Cancer Interception Research Team:
Blood-Based Early Interception of Lung Cancer

Grant Term: December 2017–November 2018

The SU2C-LUNGevity-American Lung Association (ALA) Lung Cancer Interception Research Team hypothesizes that the early detection of invasive lung cancers can be improved through new technological approaches, and that progress on this front can quickly bring about more effective patient treatments. The team is working to build a new tool―a composite of blood-based biomarker tests called the Lung Cancer Interception Assay―that can be used in conjunction with standard imaging to provide early detection of lung cancer.

ABOUT THIS TEAM’S RESEARCH

The SU2C–LUNGevity–ALA Lung Cancer Interception Research Team, building on the work of the SU2C Dream Team: Bioengineering and Clinical Applications of Circulating Tumor Cell Chip, is working to develop a Lung Cancer Interception Assay (LCIA). This test will examine circulating tumor cells and circulating tumor DNA in blood samples taken from patients, and will be used in conjunction with low-dose CT scans to provide early detection of lung cancer. If successful, the LCIA will be moved forward to larger, prospective clinical trials.

The Research Team hypothesizes that the early detection of invasive lung cancers can be improved through new technological approaches, and that progress on this front can quickly bring about more effective patient treatments.

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.